/

CCCC

C4 Therapeutics, Inc.Open

2.79−0.27 −8.99%USD

NasdaqGS · as of Oct 13, 15:49 ET · 15m delay

Open

3.04

Prev close

3.06

Day range

2.753.05

52-week range

1.695.17

Volume

3.13M1.33×

Mkt cap

342.63M

P/E ttm

—

Fwd P/E

-2.90

EPS ttm

-0.9100

Div yield

0.00%

Earnings

Aug 11, 2026

From 52w high

−46.13%

Price Chart

Yahoo Finance · delayed

CCCCOct 13, 2026O 3.04H 3.05L 2.75C 2.79−0.27 (−8.99%)Vol 3.13M

SMA 503.55
SMA 2003.14

1Y change +23.78% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CCCC C4 Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.30%
1 month: −20.66%
3 months: −26.90%
6 months: +0.91%
Year to date: +45.81%
1 year: +31.99%

Valuation & ownership

Market cap: 342.63M
Enterprise value: 179.65M
P/E (ttm): —
Forward P/E: -2.90
PEG ratio: —
Price / book: 1.38
Price / sales (ttm): 9.78
EV / EBITDA: -1.81
EPS (ttm): -0.9100
EPS (forward): -0.9620
Beta (5y monthly): 3.08
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 123.03M
Float: 94.50M
Short % of float: 33.03%
Short ratio (days): 19.61
Held by insiders: 0.84%
Held by institutions: 103.30%
Avg volume (3m): 2.36M
50-day average: 3.56
200-day average: 3.14
52-week change: +31.99%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 36.5
vs 50-day SMA: −21.45%
vs 200-day SMA: −11.44%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 8.12%
Realised vol (20d, ann.): 73.2%
From 52-week high: −46.13%
From 52-week low: +64.79%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

12.86

+361.66% implied

Low 7.00Median 10.00High 30.00

Recommendation trend

Now8 / 0 / 0
1m ago7 / 0 / 0

DES

About C4 Therapeutics, Inc.

Yahoo Finance profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 104
Headquarters: Watertown, MA, United States
Website: c4therapeutics.com
Officers: Mr. Andrew J. Hirsch M.B.A. CEO, President & Director
Dr. Kenneth C. Anderson M.D., Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board
Ms. Kendra R. Adams

SEAS

Seasonality · CCCC

2020–2026 · monthly returns

Strongest month Jul +34.34%Weakest month Mar −22.53%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.5	42.1	-2.6	7.6	54.4	6.9	-25.5	6.6	-10.2	-16.4			+45.8%
2025	-3.6	-21.9	-41.0	2.5	-23.8	14.4	43.4	26.8	-14.6	17.6	3.8	-29.5	−46.9%
2024	9.4	77.7	-25.6	-22.9	-20.6	-7.6	45.0	-5.7	-9.8	-6.5	-14.6	-20.9	−36.3%
2023	32.0	-32.3	-40.4	-3.8	12.3	-18.9	41.5	-25.4	-35.9	-19.9	9.4	246.6	−4.2%
2022	-24.1	-8.2	8.2	-64.7	-15.3	3.9	27.9	4.6	-13.0	9.7	-10.9	-31.2	−81.7%
2021	9.0	18.8	-13.8	-10.5	11.6	2.4	14.0	-7.0	11.3	-0.6	-16.4	-13.3	−2.8%
2020											38.2	-3.1	+33.9%

INSD

Insider Activity · CCCC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 17, 2026	Adams KendraChief Financial Officer	—	6.3K	—
Jul 9, 2026	Reyno LeonardOfficer	—	15.3K	—
Jun 30, 2026	Grogan Donna Roy M.D.Director	Stock Award(Grant) at price 4.34 per share.	3.3K	$14.50K
Jun 30, 2026	Anderson Kenneth CarlDirector	Stock Award(Grant) at price 4.34 per share.	2.6K	$11.50K
May 31, 2026	Anderson Kenneth CarlDirector	Conversion of Exercise of derivative security at price 2.11 per share.	1.1K	$2.26K
Mar 31, 2026	Grogan Donna Roy M.D.Director	Stock Award(Grant) at price 2.70 per share.	5.4K	$14.50K
Mar 31, 2026	Anderson Kenneth CarlDirector	Stock Award(Grant) at price 2.70 per share.	4.3K	$11.50K
Feb 12, 2026	Hirsch AndrewChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	700K	—
Feb 12, 2026	Reyno LeonardOfficer	Stock Award(Grant) at price 0.00 per share.	240K	—
Feb 12, 2026	Schick KellyOfficer	Stock Award(Grant) at price 0.00 per share.	200K	—
Feb 12, 2026	Boyle Scott NOfficer	Stock Award(Grant) at price 0.00 per share.	200K	—
Feb 12, 2026	Adams KendraChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	240K	—
Feb 12, 2026	Mossler MarkOfficer	Stock Award(Grant) at price 0.00 per share.	57K	—
Feb 12, 2026	Mahaney PaigeOfficer	Stock Award(Grant) at price 0.00 per share.	240K	—
Feb 12, 2026	Hirsch AndrewChief Executive Officer	—	102.1K	—
Feb 12, 2026	Reyno LeonardOfficer	—	30.9K	—
Feb 12, 2026	Schick KellyOfficer	—	25.9K	—
Feb 12, 2026	Boyle Scott NOfficer	—	25.9K	—
Feb 12, 2026	Adams KendraChief Financial Officer	—	34.7K	—
Feb 12, 2026	Mossler MarkOfficer	—	9.4K	—

13F

Investors Holding CCCC

latest 13F filings of 29 followed managers

Investors holding CCCC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$5.6M	0.01%	1.19M	−52%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CCCC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CCCC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About C4 Therapeutics, Inc.

Seasonality · CCCC

Insider Activity · CCCC

Congress Trades · CCCC

Investors Holding CCCC

Investors Holding CCCC

Congress Trades · CCCC

Insider Activity · CCCC

Seasonality · CCCC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About C4 Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News